[go: up one dir, main page]

EP2718270B1 - Compositions et procédés de production de composés pyrimidine et pyridine ayant une activité inhibitrice de btk - Google Patents

Compositions et procédés de production de composés pyrimidine et pyridine ayant une activité inhibitrice de btk Download PDF

Info

Publication number
EP2718270B1
EP2718270B1 EP12728011.3A EP12728011A EP2718270B1 EP 2718270 B1 EP2718270 B1 EP 2718270B1 EP 12728011 A EP12728011 A EP 12728011A EP 2718270 B1 EP2718270 B1 EP 2718270B1
Authority
EP
European Patent Office
Prior art keywords
amino
pyrimidin
phenoxyphenyl
methyl
prop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12728011.3A
Other languages
German (de)
English (en)
Other versions
EP2718270A2 (fr
Inventor
Brian L. Hodous
Lesley Liu-Bujalski
Reinaldo Jones
Donald Bankston
Theresa L. Johnson
Igor Mochalkin
Ngan NGUYEN
Hui QIU
Andreas Goutopoulos
Nadia Brugger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to SI201232002T priority Critical patent/SI2718270T1/sl
Priority to EP22169537.2A priority patent/EP4056562A1/fr
Priority to HRP20220886TT priority patent/HRP20220886T1/hr
Priority to RS20220687A priority patent/RS63418B1/sr
Publication of EP2718270A2 publication Critical patent/EP2718270A2/fr
Application granted granted Critical
Publication of EP2718270B1 publication Critical patent/EP2718270B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages

Definitions

  • the invention relates to a series of pyrimidine and pyridine compounds that are useful as therapeutics in the treatment of a variety of pathological conditions including (but not limited to) cancer, auto-immune disease, inflammatory diseases and neurodegenerative diseases in mammals. More particularly, embodiments of the present invention describe irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase (hereinafter referred to as: "BTK"). Methods for the preparation of the aforementioned compounds are disclosed in addition to the incorporation of these compounds into pharmaceutical compositions that include the same. These BTK inhibitors are disclosed for use in the treatment of hyperproliferative diseases in mammals, especially humans, as well as pharmaceutical compositions which contain said inhibitors.
  • BTK Bruton's tyrosine kinase
  • Protein kinases constitute a large family of structurally related enzymes that are responsible for the control of a wide variety of signal transduction processes within the cell ( Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Book. I and II, Academic Press, San Diego, CA ).
  • the kinases may be categorized into families by the substrates they phosphorylate (e.g., protein-tyrosine, protein-serine/threonine, lipids, etc.).
  • Protein kinases may be characterized by their regulation mechanisms. These mechanisms include, for example, autophosphorylation, transphosphorylation by other kinases, protein-protein interactions, protein-lipid interactions, and protein-polynucleotide interactions. An individual protein kinase may be regulated by more than one mechanism.
  • Kinases regulate many different cell processes including, but not limited to, proliferation, differentiation, apoptosis, motility, transcription, translation and other signalling processes, by adding phosphate groups to target proteins. These phosphorylation events act as molecular on/off switches that can modulate or regulate the target protein biological function. Phosphorylation of target proteins occurs in response to a variety of extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc.), cell cycle events, environmental or nutritional stresses, etc. The appropriate protein kinase functions in signalling pathways to activate or inactivate (either directly or indirectly), for example, a metabolic enzyme, regulatory protein, receptor, cytoskeletal protein, ion channel or pump, or transcription factor.
  • Uncontrolled signalling due to defective control of protein phosphorylation has been implicated in a number of diseases, including, for example, inflammation, cancer, allergy/asthma, diseases and conditions of the immune system, diseases and conditions of the central nervous system, and angiogenesis.
  • BTK a member of the Tec family of non-receptor tyrosine kinases, is a signaling enzyme expressed in all hematopoietic cells types except T lymphocytes and natural killer cells. BTK plays a well documented role in the B-cell signaling pathway linking cell surface B-cell receptor stimulation to downstream intracellular responses. BTK is also a regulator of B-cell development, activation, signaling, and survival ( Kurosaki, Curr Op Imm, 2000, 276-281 ; Schaeffer and Schwartzberg, Curr Op Imm 2000, 282-288 ).
  • BTK exerts a physiological effect through other hematopoetic cell signaling pathways, e.g., Toll like receptor (TLR) and cytokine receptor-mediated TNF-a production in macrophages, IgE receptor (FcepsilonRI) signaling in Mast cells, inhibition of Fas/APO-1 apoptotic signaling in B-lineage lymphoid cells, and collagen-stimulated platelet aggregation.
  • TLR Toll like receptor
  • FcepsilonRI IgE receptor
  • Fas/APO-1 Fas/APO-1 apoptotic signaling in B-lineage lymphoid cells
  • collagen-stimulated platelet aggregation e.g., BTK has an ATP-binding pocket with high similarity to Src-family kinases, such as lymphocyte-specific protein tyrosine kinase (Lck) and Lyn. Comparing BTK to other kinases one finds a conserved cysteine residue
  • BTK plays important roles in the development, differentiation, activation and proliferation of B cells, as well as their antibody and cytokine generation.
  • Btk plays a central role in other immunological processes such as cytokine production by neutrophils, mast cells and monocytes, degranulation of neutrophils and mast cells as well as differentiation/activation of osteoclasts.
  • Reversible kinase inhibitors have been developed into therapeutic compounds. These reversible inhibitors, however, have decided disadvantages. Many reversible inhibitors of kinases interact with the ATP-binding site. Given the structure of the ATP-binding sites are highly conserved among kinases, it has been difficult to develop a reversible inhibitor that selectively inhibits a desired (i.e., target) kinase. Moreover, given that many reversible kinase inhibitors readily dissociate from their target polypeptide(s), maintaining inhibition over extended periods of time can be difficult. When using reversible kinase inhibitors as therapeutics, therefore, often times near toxic dosages and/or frequent dosing is required to achieve the intended biological effect.
  • the present invention provides a series of novel pyrimidine and pyridine kinase inhibitors.
  • said kinase inhibitors are irreversible inhibitors of tyrosine kinases.
  • said irreversible kinase inhibitors inhibit BTK. While it is not intended that the compounds described by the present invention be limited to any specific mechanism of action, in some embodiments said irreversible kinase inhibitors exert a physiological effect by forming a covalent bond with Cys 481 in BTK. Significantly, this Cys 481 in BTK finds homologs in other kinases.
  • Embodiments of the present invention also described methods for synthesizing said irreversible inhibitors, said irreversible inhibitors for use in the treatment of diseases (including, but not limited to, cancer, auto-immune / inflammatory diseases, and neurodegenerative diseases). Further described are pharmaceutical Formulations that include an irreversible kinase inhibitor including pharmaceutically acceptable salts, or solvates thereof, that are kinase inhibitors and useful in the treatment of the above mentioned diseases.
  • the pyrimidine and pyridine kinase inhibitors of the present invention are also defined by Formula (II): or pharmaceutically usable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios, wherein:
  • the pyrimidine and pyridine kinase inhibitors of the present invention are also defined by Formula (IV): and pharmaceutically acceptable salts, solvates, or solvates of salts thereof, wherein:
  • substituted preferably relates to the substitution by the above-mentioned substituents, where a plurality of different degrees of substitution are possible, unless indicated otherwise.
  • the compounds of the Formula (II) and (IV) may have one or more centres of chirality. They may accordingly occur in various enantiomeric forms and be in racemic or optically active form.
  • the invention therefore also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and hydrates and solvates of these compounds.
  • the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers.
  • the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis.
  • diastereomers are formed from the mixture by reaction with an optically active resolving agent.
  • optically active acids such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitably N-protected amino acids (for example N-benzoylproline or N-benzenesulfonylproline), or the various optically active camphorsulfonic acids.
  • chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel).
  • optically active resolving agent for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel.
  • Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, such as, for example, hexane/isopropanol/ acetonitrile, for example in the ratio 82:15:3.
  • compounds of Formula (II) and Formula (IV) include isotope-labeled forms thereof.
  • An isotope-labeled form of a compound of Formula (II) and Formula (IV) is identical to this compound apart from the fact that one or more atoms of the compound have been replaced by an atom or atoms having an atomic mass or mass number which differs from the atomic mass or mass number of the atom which usually occurs naturally.
  • isotopes which are readily commercially available and which can be incorporated into a compound of the Formula (II) or Formula (IV) by well-known methods include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, for example 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F and 36 Cl, respectively. It is also contemplated that a compound of the Formula II or IV, or a pharmaceutically acceptable salt of either which contains one or more of the above-mentioned isotopes and/or other iso-topes of other atoms are embodiments of the present invention.
  • An isotope-labeled compound of the Formula II or IV can be used in a number of beneficial ways.
  • an isotope-labeled compound of the Formula II or IV into which, for example, a radioisotope, such as 3 H or 14 C, has been incorporated is suitable for medicament and/or substrate tissue distribution assays.
  • radioisotopes i.e. tritium ( 3 H) and carbon-14 ( 14 C)
  • 3 H tritium
  • 14 C carbon-14
  • Incorporation of heavier isotopes, for example deuterium ( 2 H) into a compound of the Formula II or IV may have therapeutic advantages owing to the higher metabolic stability of this isotope-labeled compound.
  • An isotope-labeled compound of the Formula II or IV can adapted to the procedures disclosed in the synthesis schemes and the related description, in the example part and in the preparation part in the present text, replacing a non-isotope-labeled reactant by a readily available isotope-labeled reactant.
  • deuterium ( 2 H) may be incorporated into a compound of Formula (II) and Formula (IV).
  • Such deuterated compounds can modify the oxidative metabolism of said deuterated compound by means the primary kinetic isotope effect.
  • the primary kinetic isotope effect is a change of the rate for a chemical reaction that results from exchange of isotopic nuclei, which in turn is caused by the change in ground state energies necessary for covalent bond formation after this isotopic exchange.
  • Exchange of a heavier isotope usually results in a lowering of the ground state energy for a chemical bond and thus causes a reduction in the rate in rate-limiting bond breakage.
  • the product distribution ratios can be altered substantially.
  • a compound of Formula (II) and Formula (IV) which has multiple potential sites of attack for oxidative metabolism for example benzylic hydrogen atoms and hydrogen atoms bonded to a nitrogen atom, is prepared as a series of analogues in which various combinations of hydrogen atoms are replaced by deuterium atoms, so that some, most or all of these hydrogen atoms have been replaced by deuterium atoms.
  • Half-life determinations enable favorable and accurate determination of the extent of the extent to which the improve-ment in resistance to oxidative metabolism has improved. In this way, it can be determined that the half-life of the parent compound may be extended by up to 100% as the result of deuterium-hydrogen exchange of this type.
  • Deuterium-hydrogen exchange in a compound of Formula (II) and Formula (IV) can also be used to achieve a favorable modification of the metabolite spectrum of the starting compound in order to diminish or eliminate undesired toxic metabolites. For example, if a toxic metabolite arises through oxidative carbon-hydrogen (C-H) bond cleavage, it can reasonably be assumed that the deuterated analogue will greatly diminish or eliminate production of the unwanted metabolite, even if the particular oxidation is not a rate-determining step. Further information on the state of the art with respect to deuterium-hydrogen exchange may be found, for example in Hanzlik et al., J. Org. Chem.
  • tautomerism e.g., keto-enol tautomerism
  • the individual forms e.g., the keto or the enol form
  • stereoisomers e.g., enantiomers, cis/trans isomers, conformers and the like.
  • isomers can be separated by methods well known in the art, e.g. by liquid chromatography. The same applies for enantiomers, e.g., by using chiral stationary phases. Additionally, enantiomers may be isolated by converting them into diastereomers, i.e., coupling with an enantiomerically pure auxiliary compound, subsequent separation of the resulting diastereomers and cleavage of the auxiliary residue. Alternatively, any enantiomer of a compound of the present invention may be obtained from stereoselective synthesis using optically pure starting materials
  • the compounds of the present invention can be in the form of a pharmaceutically acceptable salt or a solvate.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids.
  • the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts.
  • the compounds of the present invention which contain acidic groups can be present in salt form, and can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts.
  • salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids.
  • Compounds of the present invention which contain one or more basic groups, i.e. groups which can be protonated, can be present in salt form, and can be used according to the invention in the form of their addition salts with inorganic or organic acids.
  • acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art.
  • the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions).
  • inner salts or betaines can be obtained by customary methods which are known to a person skilled in the art, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts.
  • the present invention also includes all salts of the compounds of the present invention which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
  • the present invention relates to pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof as an active ingredient together with a pharmaceutically acceptable carrier.
  • “Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the present invention may additionally comprise one or more other compounds as active ingredients, such as one or more additional compounds of the present invention, or other BTK inhibitors.
  • said compounds and pharmaceutical composition are for use in the treatment of cancer such as brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, uterine, rectal, oesophageal, testicular, gynecological, thyroid cancer, melanoma, hematologic malignancies such as acute myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia, myeloid cell leukemia, glioma, Kaposi's sarcoma, or any other type of solid or liquid tumors.
  • the cancer to be treated is chosen from breast, colorectal, lung, prostate or pancreatic cancer or glioblastoma.
  • the invention also relates to the compounds according to the invention for use in the treatment of hyperproliferative diseases related to the hyperactivity of BTK as well as diseases modulated by the BTK cascade in mammals, or disorders mediated by aberrant proliferation, such as cancer or hyperactivity of B cells, mast cells, neutrophils and monocytes such in inflammatory conditions.
  • the invention also relates to a compound or pharmaceutical composition for use in treating a disease related to vasculogenesis or angiogenesis in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier.
  • said compound or pharmaceutical composition is for use in treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, Sjögren's Syndrome, atherosclerosis, skin and allegic diseases such as psoriatic arthritis, psoriasis, eczema, and sclerodema, asthma and atopic dermatitis or diseases such as diabetes, diabetic retinopathy, retinopathy of prematurity and age-related macular degeneration.
  • a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, Sjögren's Syndrome, atherosclerosis, skin and allegic diseases such as psoriatic arthritis, psoriasis, eczema, and scler
  • the BTK inhibitors for use in the treatment of rheumatoid arthritis is preferred given experimental validation which confirms the efficacy of BTK inhibitors in the treatment of collagen antibody induced arthritis and collagen induced arthritis.
  • Pan, Z. et al. Discovery of Selective Irreversible Inhibitors of Brunton's Tyrosine Kinase. ChemMedChem 2, 58-61 (2007 ). More specifically treatment with BTK inhibitors have been show to reduce the incidence and severity of collagen induced arthritis and K/BxN serum induced arthritis.
  • the compounds of the present invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like.
  • any of the usual pharmaceutical media may be employed, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.
  • the composition may take forms such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
  • tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.
  • the active compounds can also be administered intranasally as, for example, liquid drops or spray.
  • the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin.
  • a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
  • tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • Compounds of the present invention may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
  • Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention.
  • oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
  • compounds of the present invention are administered orally.
  • the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
  • the compounds of the present invention are administered at a daily dosage of from about 0.01 milligram to about 100 milligram per kilogram of animal body weight, preferably given as a single daily dose.
  • the total daily dosage is from about 0.1 milligrams to about 1000 milligrams, preferably from about 0.2 milligram to about 50 milligrams.
  • the total daily dose will generally be from about 0.2 milligrams to about 200 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
  • the invention also relates to a set (kit) consisting of separate packs of
  • the set comprises suitable containers, such as boxes, individual bottles, bags or ampoules.
  • the set may, for example, comprise separate ampoules, each containing an effective amount of a compound according to the invention and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient in dissolved or lyophilised form.
  • the compounds of the present invention can be prepared according to the procedures of the following Schemes and Examples, using appropriate materials and are further exemplified by the following specific examples. Moreover, by utilizing the procedures described herein, in conjunction with ordinary skills in the art, additional compounds of the present invention claimed herein can be readily prepared. The examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds.
  • the instant compounds are generally isolated in the form of their pharmaceutically acceptable salts, such as those described above.
  • the amine-free bases corresponding to the isolated salts can be generated by neutralization with a suitable base, such as aqueous sodium hydrogencarbonate, sodium carbonate, sodium hydroxide and potassium hydroxide, and extraction of the liberated amine-free base into an organic solvent, followed by evaporation.
  • a suitable base such as aqueous sodium hydrogencarbonate, sodium carbonate, sodium hydroxide and potassium hydroxide
  • the amine-free base, isolated in this manner can be further converted into another pharmaceutically acceptable salt by dissolution in an organic solvent, followed by addition of the appropriate acid and subsequent evaporation, precipitation or crystallization.
  • Method B nucleophilic aromatic substitution using a nitrogen nucelophile
  • Method F Amide formation from acid chloride in presence of inorganic base
  • the vial was flushed with nitrogen.
  • the reaction vial was run in a microwave for 3 hours at 150 °C.
  • the mixture was filtered, quenched in water and extracted with EtOAc (3x).
  • the combined organic layer were dried over sodium sulfate, filtered and concentrated in vacuo.
  • the crude compound was purified using Biotage column chromatography (50/50% Hexanes/ EtOAc to 100% EtOAc). Fractions containing the desired product were collected and and concentrated to afford (4-(6-amino-5-(4-phenoxyphenyl)-pyrimidin-4-ylamino)-phenyl)-acetic acid ethyl ester (1.43 g, 90 % yield) as a yellow foam.
  • Preparative HPLC was carried out on a Waters preparative HPLC system using a Waters Sunfire C18 column (5 or 10 ⁇ m).
  • Mobile phase A water with 0.1% TFA.
  • Mobile phase B acetonitrile.
  • Crude compounds were loaded on the column using a minimum volume of methanol or DMSO.
  • a typical gradient used for separation was 0-50% Mobile Phase B over 20-25 minutes with an optional wash step (100% Mobile Phase B).
  • N4-((1-(cyclopropylsulfonyl)piperidin-4-yl)methyl)-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine was prepared from 5,6-dichloropyrimidin-4-amine, tert-butyl 4-(aminomethyl)piperidine-1-carboxylate, (4-phenoxyphenyl)boronic acid, and cyclopropanesulfonyl chloride using methods B, C, D, and G.
  • HPLC purity 96 %.
  • N-(trans-3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, tert-butyl (cis-3-aminocyclohexyl)carbamate, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods B, C, D, and F.
  • HPLC purity 100 %.
  • MS: m / z 430 [M+H] + .
  • N-(5-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)pyridin-3-yl)acrylamide was prepared from 6-dichloropyrimidin-4-amine, 5-aminopyridin-3-ol, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods A, C, and F.
  • HPLC purity 97 %.
  • MS: m / z 426 [M+H] + .
  • N-(cis-3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)cyclohexyl)propiolamide was prepared from 6-dichloropyrimidin-4-amine, tert-butyl (cis-3-aminocyclohexyl)carbamate, (4-phenoxyphenyl)boronic acid, and propiolic acid using methods B, C, D, and E.
  • HPLC purity 100 %.
  • MS: m / z 428 [M+H] + .
  • N-(3-((2-amino-3-(4-(benzyloxy)phenyl)pyridin-4-yl)oxy)phenyl)acrylamide was prepared from 4-chloro-3-iodopyridin-2-amine, 3-aminophenol, (4-(benzyloxy)phenyl)boronic acid, and acryloyl chloride using methods A, C, and F.
  • HPLC 100 %.
  • MS: m / z 438 [M+H] + .
  • N-(3-((2-amino-3-(4-phenoxyphenyl)pyridin-4-yl)oxy)-4-fluorophenyl)acrylamide was prepared from 4-chloro-3-iodopyridin-2-amine, 5-amino-2-fluorophenol, (4-phenoxyphenyl)boronic acid and acryloyl chloride using methods A, C, and F.
  • HPLC 100%.
  • MS: m / z 442 [M+H] + .
  • N-(3-((6-amino-5-(6-phenoxypyridin-3-yl)pyrimidin-4-yl)oxy)-4-fluorophenyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, 5-amino-2-fluorophenol, 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, and acryloyl chloride using methods A, C, and F.
  • HPLC 100 %.
  • N-(3-((6-amino-5-(4-(pyridin-2-yloxy)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, 3-aminophenol, 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine, and acryloyl chloride using methods A, C, and F.
  • HPLC 100 %.
  • N-(3-((6-amino-5-(3-(trifluoromethoxy)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, 3-aminophenol, (3-(trifluoromethoxy)phenyl)boronic acid, and acryloyl chloride using methods A, C, and F.
  • HPLC 100 %.
  • N-(3-((6-amino-5-(6-(2-fluorophenoxy)pyridin-3-yl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, 3-aminophenol, 2-(2-fluorophenoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, and acryloyl chloride using methods A, C, and F.
  • HPLC 99 %.
  • N-(3-((6-amino-5-(6-(4-fluorophenoxy)pyridin-3-yl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, 3-aminophenol, 2-(4-fluorophenoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, and acryloyl chloride using methods A, C, and F.
  • HPLC 99 %.
  • N-(6-((5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)pyridin-2-yl)acrylamide was prepared from 5-bromo-4-chloropyrimidine, pyridine-2,6-diamine, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods H, C, and F.
  • MS: m / z 410 [M+H] + .
  • N-((1S,3R)-3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, tert-butyl (cis-3-aminocyclohexyl)carbamate, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods B, C, D, F and chiral separation.
  • HPLC 95 %.
  • N-((1R,3S)-3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, tert-butyl (cis-3-aminocyclohexyl)carbamate, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods B, C, D, F and chiral separation.
  • HPLC 98 %.
  • N-((1R,3R)-3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, tert-butyl (trans-3-aminocyclohexyl)carbamate, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods B, C, D, F and chiral separation.
  • HPLC 98 %.
  • N-((1S,3S)-3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, tert-butyl (trans-3-aminocyclohexyl)carbamate, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods B, C, D, F and chiral separation.
  • HPLC 97 %.
  • N-(4-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)bicyclo[2.1,1]hexan-1-yl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, benzyl (4-aminobicyclo[2.1.1]hexan-1-yl)carbamate hydrochloride, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods B, C, hydrogenation, and F.
  • HPLC 100 %.
  • N-(cis-3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)cyclopentyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, tert-butyl (cis-3-aminocyclopentyl)carbamate, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods B, C, D, and F.
  • N-(3-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)cyclobutyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, tert-butyl (3-(aminomethyl)cyclobutyl)carbamate, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods B, C, D, and F.
  • HPLC 100 %.
  • N-(5-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)pyridin-3-yl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, pyridine-3,5-diamine, (4-phenoxyphenyl)boronic acid, and acryloyl chloride using methods J, C, and F.
  • HPLC 100 %.
  • N-(5-((6-amino-5-(4-(4-cyanophenoxy)phenyl)pyrimidin-4-yl)oxy)pyridin-3-yl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, 5-aminopyridin-3-ol dihydrochloride, 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)benzonitrile, and acryloyl chloride using methods A, C, and F.
  • HPLC 98 %.
  • N-(3-((6-amino-5-(4-(3-cyanophenoxy)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 5,6-dichloropyrimidin-4-amine, 3-aminophenol, 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)benzonitrile, and acryloyl chloride using methods A, C, and F.
  • HPLC 98 %.
  • 1-acryloyl-4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidine-4-carboxylic acid was prepared 5,6-dichloropyrimidin-4-amine, 4-phenoxyphenylboronic acid 4-(aminomethyl)-1-( tert -butoxycarbonyl)piperidine-4-carboxylic acid carboxylate and acrylic acid with method S1, S2, S3, S4A. Yield 35.9%.
  • N -(1,3- trans -3-((6-amino-5-(4-(3-(trifluoromethyl)phenoxy)phenyl)pyrimidin-4-yl)amino)cyclobutyl)acrylamide was prepared 5,6-dichloropyrimidin-4-amine, (4-(3-(trifluoromethyl)phenoxy)phenyl)boronic acid, tert -butyl (1,3-trans-3- aminocyclobutyl)carbamate and acrylic acid with method S1, S2, S3, S4A. Yield 22.8%.
  • N -(1,3- cis -3-((6-amino-5-(4-(3-(trifluoromethyl)phenoxy)phenyl)pyrimidin-4-yl)amino)cyclobutyl)acrylamide was prepared 5,6-dichloropyrimidin-4-amine, (4-(3-(trifluoromethyl)phenoxy)phenyl)boronic acid, tert -butyl(1,3-cis-3-aminocyclobutyl)carbamate and acrylic acid with method S1, S2, S3, S4A. Yield 22.1%.
  • N-(3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)-2-fluorophenyl)acrylamide was prepared from 6-(3-amino-2-fluorophenoxy)-5-(4-phenoxyphenyl)pyrimidin-4-amine using Method F (82 % yield).
  • N-(3-(4-amino-6-((4-phenoxyphenyl)amino)pyrimidin-5-yl)phenyl)acrylamide was prepared from 5-(3-aminophenyl)-N4-(4-phenoxyphenyl)pyrimidine-4,6-diamine using Method E (21 % yield).
  • N-(3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 6-(3-aminophenoxy)-5-(4-phenoxyphenyl)pyrimidin-4-amine using Method E (20 % yield).
  • N-(3-((2-amino-3-(4-phenoxyphenyl)pyridin-4-yl)oxy)phenyl)acrylamide was prepared from 4-(3-aminophenoxy)-3-(4-phenoxyphenyl)pyridin-2-amine using Method F (52 % yield).
  • N-(3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)-4-fluorophenyl)acrylamide was prepared from 6-(5-amino-2-fluorophenoxy)-5-(4-phenoxyphenyl)pyrimidin-4-amine using Method F (6 % yield).
  • N-(5-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)-2,4-difluorophenyl)acrylamide was prepared from 6-(5-amino-2,4-difluorophenoxy)-5-(4-phenoxyphenyl)pyrimidin-4-amine using Method F (10 % yield).
  • N-(3-((5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 3-((5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)aniline using Method F (86 % yield).
  • N-(3-((6-amino-2'-(benzyloxy)-[5,5'-bipyrimidin]-4-yl)oxy)phenyl)acrylamide was prepared from 6-(3-aminophenoxy)-2'-(benzyloxy)-[5,5'-bipyrimidin]-4-amine using Method F (46 % yield).
  • N-(3-((6-amino-5-(4-((4-methoxybenzyl)oxy)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 6-(3-aminophenoxy)-5-(4-((4-methoxybenzyl)oxy)phenyl)pyrimidin-4-amine using Method F (35 % yield).
  • N-((1s,4s)-4-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide was prepared from N4-((1s,4s)-4-aminocyclohexyl)-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine using Method F (20 % yield).
  • N-(3-((6-amino-5-(6-phenoxypyridin-3-yl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 6-(3-aminophenoxy)-5-(6-phenoxypyridin-3-yl)pyrimidin-4-amine using Method F (70 % yield).
  • N-(3-((3-(4-phenoxyphenyl)pyridin-4-yl)oxy)phenyl)acrylamide was prepared from 3-((3-(4-phenoxyphenyl)pyridin-4-yl)oxy)aniline using Method E (36 % yield).
  • N-(3-((2-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 4-(3-aminophenoxy)-5-(4-phenoxyphenyl)pyrimidin-2-amine using Method E (11 % yield).
  • N-((1r,4r)-4-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide was prepared from N4-((1r,4r)-4-aminocyclohexyl)-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine using Method F (13 % yield).
  • N-(3-((6-amino-5-(4-fluoro-3-methoxyphenyl)pyrimidin-4-yl)oxy)phenyl)acrylam ide was prepared from 6-(3-aminophenoxy)-5-(4-fluoro-3-methoxyphenyl)pyrimidin-4-amine using Method E (13 % yield).
  • N-(3-((6-amino-5-(4-(2-hydroxypropan-2-yl)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 2-(4-(4-amino-6-(3-aminophenoxy)pyrimidin-5-yl)phenyl)propan-2-ol using Method E (22 % yield).
  • N-(4-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 6-(4-aminophenoxy)-5-(4-phenoxyphenyl)pyrimidin-4-amine using Method E (23 % yield).
  • N-(3-((6-amino-5-(4-isopropoxyphenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 6-(3-aminophenoxy)-5-(4-isopropoxyphenyl)pyrimidin-4-amine using Method F (79 % yield).
  • N-(3-((6-amino-5-(5-methoxypyridin-3-yl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 6-(3-aminophenoxy)-5-(5-methoxypyridin-3-yl)pyrimidin-4-amine using Method E (13 % yield).
  • N-(4-((3-(4-phenoxyphenyl)pyridin-4-yl)oxy)phenyl)acrylamide was prepared from 4-((3-(4-phenoxyphenyl)pyridin-4-yl)oxy)aniline using Method E (41 % yield).
  • N-(1-(6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)piperidin-3-yl)acrylamide was prepared from 6-(3-aminopiperidin-1-yl)-5-(4-phenoxyphenyl)pyrimidin-4-amine using Method F (14 % yield).
  • N-(4-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide was prepared from 6-(4-aminophenoxy)-5-(4-phenoxyphenyl)pyrimidin-4-amine and propionic acid using Method E (51 % yield).
  • N-((1-(6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)piperidin-3-yl)methyl)acrylamide was prepared from 6-(3-(aminomethyl)piperidin-1-yl)-5-(4-phenoxyphenyl)pyrimidin-4-amine using Method F (43 % yield).
  • N-(4-((3-(4-phenoxyphenyl)pyridin-4-yl)oxy)phenyl)propionamide was prepared from 4-((3-(4-phenoxyphenyl)pyridin-4-yl)oxy)aniline using Method E (98 % yield).
  • N-(3-((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)oxy)phenyl)propionamide was prepared from 6-(3-aminophenoxy)-5-(4-phenoxyphenyl)pyrimidin-4-amine using Method E (61 % yield).
  • N4-((1-(6-chloropyridin-2-yl)piperidin-4-yl)methyl)-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine was prepared from 5-(4-phenoxyphenyl)-N4-(piperidin-4-ylmethyl)pyrimidine-4,6-diamine and 2,6-dichloropyridine using Method B (25 % yield).
  • HPLC 99 %, RT: 5.214 min.
  • N-(3-((2-amino-3-(4-phenoxyphenyl)pyridin-4-yl)oxy)phenyl)but-2-ynamide was prepared from 4-(3-aminophenoxy)-3-(4-phenoxyphenyl)pyridin-2-amine using Method E (13 % yield).
  • HPLC 98 %, RT: 4.676 min.
  • N- ⁇ 4-[4-(3-Acryloylamino-phenoxy)-6-amino-pyrimidin-5-yl]-phenyl ⁇ -benzamide was produced according to Method E (8.8 % yield).
  • kinase reaction buffer consisting of 25 mM MgCl2, 0.015% Brij-35 (30%), 100 mM Hepes, pH 7.5, and 10 mM DTT.
  • Table 2 presents IC 50 values, derived from the in vitro assays detailed above, for selected compounds described by embodiments of the present invention.
  • Table 2 Compound No. Time Dependent BTK Enzyme Assay IC 50 Time Dependent Human Whole Blood BTK Enzyme Assay IC 50 Time Dependent PBMC Assay IC 50 "A1" A I I "A2" - - - "A3” A I I "A4" A I I "A6” A - I "A8" - - - "A9” A - - "A10” A - I "A11” C - - "A12” - - - "A13” C - - "A14” - - - "A15” - - - "A16” C - - "A17” A - - "A19” A - - "A21” A - - "A23” - - - "A25” C - - “A26” A
  • SLE Systemic Lupus Erythematosus Mouse Model
  • CPD. B 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one, designated as "CPD. B", was evaluated in an interferon-alpha accelerated SLE mouse model.
  • NZB/W F1 mice received i.v. injection at day 0 and day 1 of 10 8 infectious units of adenovirus (ADV-IFN- ⁇ ) to deliver a transient overexpression on interferon alpha.
  • Oral dosing of the different group treatments was initiated on day 14 and continued daily at 24 hour intervals until the end of the study.
  • Treatment groups consisted of 20% Kleptose HPB in Na-citrate buffer (vehicle) or 0.1, 0.3, 1, or 3 mg/kg of Cpd.
  • Disease activity (0.5 * (days with proteinuria of individual animal/mean of days with proteinuria of vehicle group) + 0.5 *(AUC of individual animal/mean AUC of vehicle group))*100.
  • Fig. 2 presents data from another interferon-alpha accelerated SLE experiment in mice. NZB/W F1 mice received i.v.
  • CPD 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one, designated as "CPD. A”, was evaluated in a collagen-induced arthritis model in rats. Anesthetized female Lewis rats received subcutaneous/intradermal injections of 300 ⁇ l of Freund's Incomplete Adjuvant containing 4 mg/ml bovine type II collagen, at the base of the tail and 2 sites on the back on days 0 and 6. Figure 3 presents data from the oral dosing of the different group treatments was initiated on day 6 and continued daily at 24 hour intervals, for 11 days up to day 16.
  • Treatment groups consisted of 20% Hydroxy-Propyl-Beta Cyclodextrin in H 2 O (vehicle) or 0.3, 1, 3, or 10 mg/kg of Cpd. A, or methotrexate (MTX) at 0.1 mg/kg. Caliper measurements of ankles were taken every day beginning on day 9 (or day 0 of arthritis). Animals were sacrificed on day 17.
  • CPD collagen-induced arthritis model
  • Male DBA/1OIaHsd mice were injected intradermally at the base of the tail with 150 ⁇ l of Freund's Complete Adjuvant containing bovine type II collagen on day 0 and on day 21.
  • Figure 4 presents data from this experiment. On day 18, mice were randomized by body weight into treatment groups. Oral treatment was initiated after enrollment on day 18 and continued daily at 24 h intervals up to day 33.
  • mice were treated with 20% Hydroxy-Propyl-Beta Cyclodextrin in H 2 O (vehicle) or Cpd. A at either 1, 3, 10, or 30 mg/kg or with methotrexate (MTX) at 0.5 mg/kg.
  • MTX methotrexate
  • PCA Mouse Passive cutaneous anaphylaxis
  • CPD 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one, designated as "CPD. B”, was evaluated in a PCA model in mice.
  • anaphylaxis mediated through the Fc ⁇ RI receptor is a mast-cell-dependent allergic response to local or systemic exposure to allergens, which cross-link and activate antigen-specific IgE bound to the Fc ⁇ RI on the mast cell surface leading to mast cell activation and degranulation.
  • FIG. 5 presents data from experiments where10-week old female BALB/c mice were injected intradermally with immunoglubulin E (IgE) directed against the hapten 2,4-dinitrophenyl (DNP). 24h after sensitization, mice were challenged by systemic administration of DNP coupled to human serum albumin (HSA), together with Evan's blue dye. Mice were dosed orally with three doses of Cpd B. 1h before challenge. Evan's blue extravasation was measured in the back 30 minutes after the challenge.
  • IgE immunoglubulin E
  • HSA human serum albumin
  • CPD 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one, designated as "CPD. B”
  • BCR activation induces the expression of the surface cluster of differentiation 69 (CD69) which is the earliest inducible cell surface glycoprotein acquired during lymphoid activation and is currently used as a marker for B cell activation both in vitro and ex vivo.
  • Female C57BI/6 mice were administered orally with Cyclodextrin or 1.19, 3.96 or 11.9 mg/kg of Cpd. A 1h before blood collection.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Claims (10)

  1. Composé de la formule II
    Figure imgb0287
     ou sel, forme tautomère ou stéréoisomère pharmaceutiquement utilisable correspondant(e), y compris des mélanges de ceux-ci en tous rapports,
    X étant H ou CH3 ou NH2,
    Y étant absent,
    B étant N ou CH,
    E étant NH2 ou H,
    W étant NR ou O,
    Z étant, indépendamment, CH2, CH2-CH2 ou NH ou étant absent,
    « lieur » étant un groupe choisi parmi un cycle aryle, un cycle hétéroaryle, un hétérocycle saturé ou partiellement insaturé à 4 à 7 chaînons possédant 1 à 3 hétéroatomes indépendamment choisis parmi azote et oxygène, ou un cycle hétérocyclique saturé ou partiellement insaturé à 7 à 10 chaînons possédant 1 à 5 hétéroatomes indépendamment choisis parmi azote et oxygène, ou un cycle hétérocyclique bicyclique saturé ou partiellement insaturé à 7 à 10 chaînons possédant 1 à 5 hétéroatomes fixés à un cycle hétérosaturé, des cycloalcanes éventuellement substitués par OH,
    A étant un homocycle ou hétérocycle aromatique monocyclique possédant 0, 1, 2, 3 ou 4 atomes de
    N et/ou O et 5, 6, 7, 8, 9 ou 10 atomes de C de squelette,
    Hal étant F, Cl, Br ou I,
    R étant indépendamment hydrogène, oxygène ou un groupe choisi parmi aliphatique linéaire en C1-6, un cycle hétérocyclique à 4 à 7 chaînons possédant 1 à 2 hétéroatomes indépendamment choisis parmi azote, oxygène, ou un homocycle ou hétérocycle aromatique monocyclique ou bicyclique possédant 0, 1, 2, 3 ou 4 atomes de N, O et et 5, 6, 7 ou 8 atomes de C de squelette, qui peut être non substitué ou, indépendamment d'un autre, monosubstitué, disubstitué ou trisubstitué par Hal, A, OH, NH2, nitrile et/ou C(Hal)3 ou étant un alkyle linéaire non ramifié ou ramifié possédant 1, 2, 3, 4, 5, 6, 7 ou 8 atomes de C, dans lequel un ou deux groupes CH2 peuvent être remplacés par un atome de O et/ou par un groupe -NH-, -CO-, -NHCOO-, -NHCONH-,-CONH-, -NHCO- ou -CH=CH-, et dans lequel 1 à 3 atomes de H peuvent être remplacés par Hal,
    Rq étant choisi parmi --R, --A, halogène,-O(CH2)rOR, --R(NH), --NO2, --C(O)R, --C(O)2R,-C(O)N(R)2, --NRC(O)R, --NRC(O)NR2, --NRSO2R ou --N(R)2,
    r étant 1 à 4,
    n étant 0 à 4, et
    Q étant
    Figure imgb0288
    Figure imgb0289
    Figure imgb0290
    Figure imgb0291
    Figure imgb0292
    Figure imgb0293
    Figure imgb0294
    Figure imgb0295
    Figure imgb0296
  2. Composé selon la revendication 1, Q étant
    Figure imgb0297
    Figure imgb0298
    Figure imgb0299
  3. Composé selon la revendication 1, de formule (IV) :
    Figure imgb0300
    ou sel, solvate ou solvate de sel pharmaceutiquement acceptable correspondant,
    Z étant N ou CH,
    X étant O ou NH, et
    R3 étant choisi dans le groupe constitué par les structures suivantes :
    Figure imgb0301
    Figure imgb0302
  4. Composé choisi dans le groupe N° Nom chimique « A1 » (R)-1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pyrrolidin-1-yl)prop-2-én-1-one « A2 » (R)-1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)pipéridin-1-yl)prop-2-én-1-one « A3 » N-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)phényl)acrylamide « A4 » (R)-1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pyrrolidin-1-yl)prop-2-én-1-one « A6 » 1-(4-(((5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)méthyl)pipéridin-1-yl)prop-2-én-1-one « A8 » 4-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridine-1-carbonyl)-1-méthylpyridin-2(1H)-one « A9 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)méthyl)pipéridin-1-yl)but-2-yn-1-one « A10 » 5-(4-phénoxyphényl)-N4-((1-(vinylsulfonyl)pipéridin-4-yl)méthyl)pyrimidin-4,6-diamine « A11 » (E)-1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)-4-((2-méthoxyéthyl) (méthyl)amino)but-2-én-1-one « A12 » (4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl) (2-fluoropyridin-3-yl)méthanone « A13 » (E)-1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)but-2-én-1-one « A14 » N4-((1-(cyclopropylsulfonyl)pipéridin-4-yl)méthyl)-5-(4-phénoxyphényl)pyrimidin-4,6-diamine « A15 » (Z)-1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4- yl)amino)méthyl)pipéridin-1-yl)but-2-én-1-one « A16 » 1-(4-(2-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)éthyl)pipéridin-1-yl)prop-2-én-1-one « A17 » 1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)méthyl)pipéridin-1-yl)prop-2-én-1-one « A19 » (R)-1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)pyrrolidin-1-yl)prop-2-én-1-one « A21 » 1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)méthyl)pyrrolidin-1-yl)prop-2-én-1-one « A23 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)éthanone « A25 » 1-(4-(((2-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A26 » (S)-1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)méthyl)pyrrolidin-1-yl)prop-2-én-1-one « A28 » (S)-1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pyrrolidin-1-yl)prop-2-én-1-one « A29 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)-2-méthylprop-2-én-1-one « A30 » (4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl) (cyclohex-1-en-1-yl)méthanone « A31 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)-3-méthylbut-2-én-1-one « A32 » (4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl) (cyclopent-1-en-1-yl)méthanone « A34 » 1-(4-(((6-amino-5-(4-(3-fluorophénoxy)phényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A36 » 1-(4-(((6-amino-2-méthyl-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A37 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-4-hydroxypipéridin-1-yl)prop-2-én-1-one « A38 » (R)-1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)méthyl)pyrrolidin-1-yl)prop-2-én-1-one « A39 » 1-(4-(((6-amino-5-(4-(phénylamino)phényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A40 » 1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)-1H-pyrrol-2(5H)-one « A41 » 1-(4-(((6-amino-5-(4-benzylphényl)pyrimidin-4- yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A42 » (4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl) (cyclobut-1-en-1-yl)méthanone « A43 » (Z)-1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)méthyl)pipéridin-1-yl)but-2-én-1-one « A44 » 1-(4-(((6-amino-2-méthyl-5-(4-phénoxyphényl)pyrimidin-4-yl)(méthyl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A45 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)-2-chloréthanone « A46 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-yn-1-one « A47 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)(méthyl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A48 » 1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-8-azabicyclo[3.2.1 ]octan-8-yl)prop-2-én-1-one « A49 » N-((1S,3S)-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclopentyl)acrylamide « A51 » N-(cis-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide « A52 » 1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)azépan-1-yl)prop-2-én-1-one « A53 » N-(trans-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide « A54 » (E)-5-(4-phénoxyphényl)-N4-((1-(styrylsulfonyl)pipéridin-4-yl)méthyl)pyrimidin-4,6-diamine « A55 » N4-((1-(méthylsulfonyl)pipéridin-4-yl)méthyl)-5-(4-phénoxyphényl)pyrimidin-4,6-diamine « A56 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)-2,3-dihydroxypropan-1-one « A60 » N-(5-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)pyridin-3-yl)acrylamide « A61 » (R)-1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pyrrolidin-1-yl)prop-2-yn-1-one « A62 » (R,E)-1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pyrrolidin-1-yl)-4-(diméthylamino)but-2-én-1-one « A63 » (E)-N-(cis-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclohexyl)-4-(diméthylamino)but-2-énamide « A64 » N-(cis-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino) cyclohexyl)propiolamide « A65 » (S)-1-(2-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4- yl)oxy)méthyl)morpholino)prop-2-én-1-one « A66 » (R)-1-(2-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)méthyl)morpholino)prop-2-én-1-one « A68 » 1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-8-azabicyclo[3.2.1 ]octan-8-yl)prop-2-yn-1-one « A71 » (E)-1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-8-azabicyclo[3.2.1 ]octan-8-yl)-4-(diméthylamino)but-2-én-1-one « A73 » (R,E)-1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pyrrolidin-1-yl)-4-(diméthylamino)but-2-én-1-one « A74 » (R,E)-1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pipéridin-1-yl)-4-(diméthylamino)but-2-én-1-one « A75 » 1-(trans-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-4-hydroxypyrrolidin-1-yl)prop-2-én-1-one « A76 » 1-(4-(((2-amino-3-(4-phénoxyphényl)pyridin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A77 » 1-(4-(((6-amino-5-(4-fluorophényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A78 » 1-(4-(((6-amino-5-(4-(trifluorméthoxy) phényl) pyrimidin-4- yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A79 » 1-(4-(((6-amino-5-(4-(4-(trifluorméthyl) phénoxy) phényl) pyrimidi n-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A80 » 1-(4-(((6-amino-5-(4-(4-(fluorophénoxy)phényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A82 » 1-(4-(((6-amino-5-(3,4-diméthoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A83 » 1-(4-(((6-amino-5-(3,4,5-triméthoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A85 » 1-(4-(((6-amino-5-(4-méthoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A87 » 1-(4-(((6-amino-5-(2,5-difluor-4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A88 » 1-(4-(((6-amino-5-(2,3-difluor-4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A90 » 1-(4-(((6-amino-5-(4-phénoxy-2-(trifluorméthyl) phényl) pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A94 » 1-(4-(((6-amino-5-(4-(4-hydroxyphénoxy)phényl)pyrimidin-4- yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A95 » 1-(4-(((6-amino-5-(4-(3-(trifluorméthyl) phénoxy) phényl) pyrimidi n-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A96 » 1-(4-(((6-amino-5-(4-(pyridin-3-yloxy) phényl) pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A97 » 1-(4-(((6-amino-5-(4-(pyridin-4-yloxy) phényl) pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A98 » 1-(4-(((6-amino-5-(4-(p-tolyloxy)phényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A103 » 1-(3-(2-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)éthyl)azétidin-1-yl)prop-2-én-1-one « A104 » 1-(3-(2-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)éthyl)azétidin-1-yl)prop-2-yn-1-one « A105 » (E)-1-(6-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)-2-azaspiro[3.3]heptan-2-yl)-4-(diméthylamino)but-2-én-1-one « A108 » 1-(6-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-2-azaspiro[3.3]heptan-2-yl)but-2-yn-1-one « A113 » 1-(2-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-6-azaspiro[3.4]octan-6-yl)prop-2-én-1-one « A114 » 1-(6-((6-amino-5-(4-(pyridin-4-yloxy)phényl)pyrimidin-4-yl)oxy)-2-azaspiro[3.3]heptan-2-yl)prop-2-én-1-one « A115 » 1-(2-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-6-azaspiro[3.4]octan-6-yl)prop-2-yn-1-one « A116 » 1-(6-((6-amino-5-(1-(pyridin-4-ylméthyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)amino)-2-azaspiro[3.3]heptan-2-yl)prop-2-én-1-one « A117 » N-(1,3-trans-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclobutyl)acrylamide « A118 » N-((1,3-cis-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclobutyl)acrylamide « A119 » N4-(2-((2-Chloréthyl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-5-(4-phénoxyphényl)pyrimidin-4,6-diamine « A120 » 1-(6-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)-2-azaspiro[3.3]heptan-2-yl)prop-2-én-1-one « A121 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-4-méthoxypipéridin-1-yl)prop-2-én-1-one « A122 » N-(6-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)spiro[3.3]heptan-2-yl)acrylamide « A123 » 1-(1-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-7-azaspiro[3.5]nonan-7-yl)prop-2-én-1-one « A124 » 1-(6-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-2- azaspiro[3.3]heptan-2-yl)prop-2-én-1-one « A125 » 1-(8-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-5-azaspiro[3.5]nonan-5-yl)prop-2-én-1-one « A126 » (E)-1-((3S,4S)-4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-3-hydroxypipéridin-1-yl)-4-(diméthylamino)but-2-én-1-one « A127 » (E)-1-(6-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-2-azaspiro[3.3]heptan-2-yl)-4-(diméthylamino)but-2-én-1-one « A141 » 1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-ylamino)méthyl)phényl)but-2-yn-1-one « A142 » 1-(3-((6-amino-5-(4-phénoxyphényl)-pyrimidin-4-ylamino)méthyl)phényl) but-2-én-1-one « A143 » 1-((1S,3S)-3-(6-amino-5-(4-phénoxyphényl)pyrimidin-4-ylamino)cyclohexyl)propénone « A144 » 1-((1S,3S)-3-(6-amino-5-(4-phénoxyphényl)pyrimidin-4-ylamino)cyclohexyl)-but-2-én-1-one « A145 » 1-((1S,3S)-3-(6-amino-5-(4-phénoxyphényl)pyrimidin-4-ylamino)cyclohexyl)-but-2-yn-1-one « A146 » 1-((1S,3R)-3-(6-amino-5-(4-phénoxyphényl)-pyrimidin-4-ylamino)-cyclohexyl)-but-2-én-1-one « A147 » 1-((1S,3R)-3-(6-amino-5-(4-phénoxyphényl)-pyrimidin-4-ylamino)-cyclohexyl)-but-2-yn-1-one « A148 » (S)-1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4- yl)amino)pyrrolidin-1-yl)prop-2-én-1-one « A149 » N-(3-((2-amino-3-(4-(benzyloxy)phényl)pyridin-4-yl)oxy)phényl)acrylamide « A150 » 1-(3-((2-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pipéridin-1-yl)prop-2-én-1-one « A151 » (E)-N-(3-((2-amino-3-(4-phénoxyphényl)pyridin-4-yl)oxy)phényl)-4-(diméthylamino)but-2-énamide « A153 » (E)-1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)-4-(diméthylamino)but-2-én-1-one « A155 » 4-(4-(((1-acryloylpyrrolidin-3-yl)méthyl)amino)-6-aminopyrimidin-5-yl)-N-phénylbenzamide « A157 » 4-(4-(((1-acryloylpipéridin-4-yl)méthyl)amino)-6-aminopyrimidin-5-yl)-N-phénylbenzamide « A158 » N-(3-((2-amino-3-(4-phénoxyphényl)pyridin-4-yl)oxy)-4-fluorophényl)acrylamide « A159 » 4-(4-((cis-4-acrylamideocyclohexyl)amino)-6-aminopyrimidin-5-yl)-N-phénylbenzamide « A160 » (E)-1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pipéridin-1-yl)-4-(diméthylamino)but-2-én-1-one « A161 » N-(3-((6-amino-5-(6-phénoxypyridin-3-yl)pyrimidin-4-yl)oxy)-4-fluorophényl)acrylamide « A162 » N-(3-((6-amino-5-(4-(pyridin-2-yloxy) phényl) pyrimidin-4-yl)oxy)phényl)acrylamide « A164 » N-(3-((6-amino-5-(3-(trifluorméthoxy) phényl) pyrimidin-4-yl)oxy)phényl)acrylamide « A165 » N-(3-((6-amino-5-(6-(2-fluorophénoxy)pyridin-3-yl)pyrimidin-4-yl)oxy)phényl)acrylamide « A166 » N-(3-((6-amino-5-(6-(4-fluorophénoxy)pyridin-3-yl)pyrimidin-4-yl)oxy)phényl)acrylamide « A167 » N-(6-((5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pyridin-2-yl)acrylamide « A168 » 1-(4-(((6-amino-5-(6-phénoxypyridin-3-yl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A169 » 1-(4-(((6-amino-5-(4-(3-(trifluorméthyl) phénoxy) phényl) pyrimidi n-4-yl)amino)méthyl)-4-hydroxypipéridin-1-yl)prop-2-én-1-one « A170 » 1-((3S,4S)-4-(((6-amino-5-(4-(3-(trifluorméthyl) phénoxy) phényl) pyrimidi n-4-yl)amino)méthyl)-3-hydroxypipéridin-1-yl)prop-2-én-1-one « A171 » 1-(4-(((6-amino-2'-phénoxy-[5,5'-bipyrimidin]-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A173 » N-((1S,3R)-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide « A174 » N-((1R,3S)-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide « A175 » N-((1R,3R)-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide « A176 » N-((1S,3S)-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide « A177 » N-(4-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)bicyclo[2.1.1]hexan-1-yl)acrylamide « A178 » (R)-N4-(1-((perfluorophényl)sulfonyl)pyrrolidin-3-yl)-5-(4-phénoxyphényl)pyrimidin-4,6-diamine « A179 » (R)-N4-(1-((perfluorophényl)sulfonyl)pipéridin-3-yl)-5-(4-phénoxyphényl)pyrimidin-4,6-diamine « A181 » N-(cis-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclopentyl)acrylamide « A182 » N-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)cyclobutyl)acrylamide « A185 » 1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)azétidin-1-yl)prop-2-én-1-one « A186 » N-(5-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pyridin-3-yl)acrylamide « A188 » N-((1R,3S,5R)-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-5-hydroxycyclohexyl)acrylamide (racémique) « A197 » N-(5-((6-amino-5-(4-(4-cyanophénoxy) phényl) pyrimidin-4-yl)oxy)pyridin-3-yl)acrylamide « A199 » 4-(4-(4-((((3S,4S)-1-acryloyl-3-hydroxypipéridin-4-yl)méthyl)amino)-6- aminopyrimidin-5-yl)phénoxy) benzonitrile « A200 » (R)-4-(4-(4-((4-acryloylmorpholin-2-yl)méthoxy)-6-aminopyrimidin-5-yl)phénoxy) benzonitrile « A201 » (R)-4-(4-(4-((1-acryloylpyrrolidin-3-yl)méthoxy)-6-aminopyrimidin-5-yl)phénoxy) benzonitrile « A202 » 4-(4-(4-((2-acryloyl-2-azaspiro[3.3]heptan-6-yl)oxy)-6-aminopyrimidin-5-yl)phénoxy)benzonitrile « A204 » 1-((3S,5S)-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-5-fluoropipéridin-1-yl)prop-2-én-1-one « A205 » 1-((3R,5R)-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-5-fluoropipéridin-1-yl)prop-2-én-1-one « A206 » 3-((4-(4-(3-acrylamideophénoxy)-6-aminopyrimidin-5-yl)-1H-pyrazol-1-yl)méthyl)benzoate de méthyle « A207 » 4-(4-(4-((2-acryloyl-2-azaspiro[3.3]heptan-6-yl)amino)-6-aminopyrimidin-5-yl)phénoxy) benzonitrile « A208 » 4-(4-(4-(((8-acryloyl-8-azabicyclo[3.2.1]octan-3-yl)méthyl)amino)-6-aminopyrimidin-5-yl)phénoxy) benzonitrile « A210 » 1-((3R,4R)-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-4-hydroxypipéridin-1-yl)prop-2-én-1-one (racémique) « A213 » N-(3-((6-amino-5-(4-(3-cyanophénoxy) phényl) pyrimidin-4-yl)oxy)phényl)acrylamide « A214 » 3-(4-(4-(((1-acryloylpipéridin-4-yl)méthyl)amino)-6-aminopyrimidin-5-yl)phénoxy) benzonitrile « A215 » 1-((3S,4S)-4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-3-hydroxypipéridin-1-yl)but-2-yn-1-one « A216 » acide 1-acryloyl-4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-4-carboxylique « A217 » acide (E)-4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-1-(4-(diméthylamino)but-2-enoyl)pipéridin-4-carboxylique « A218 » (E)-1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)-4-(3-fluorazétidin-1-yl)but-2-én-1-one « A219 » (E)-1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)-4-(3,3-difluorazétidin-1-yl)but-2-én-1-one « A220 » (E)-1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)-4-(pyrrolidin-1-yl)but-2-én-1-one « A221 » 1-(6-((6-amino-5-(4-(pyridin-3-yloxy)phényl)pyrimidin-4-yl)oxy)-2-azaspiro[3.3]heptan-2-yl)prop-2-én-1-one « A222 » (E)-1-(6-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)-2-azaspiro[3.3]heptan-2-yl)-4-(3-fluorazétidin-1-yl)but-2-én-1-one « A223 » (E)-1-(6-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)-2-azaspiro[3.3]heptan-2-yl)-4-(3-fluorazétidin-1-yl)but-2-én-1-one « A224 » (E)-N-(1,3-cis-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino) cyclobutyl)-4-(diméthylamino)but-2-énamide « A225 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-4-fluoropipéridin-1-yl)prop-2-én-1-one « A226 » (E)-1-(2-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)-6-azaspiro[3.4]octan-6-yl)-4-(diméthylamino)but-2-én-1-one « A227 » (E)-1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-4-fluoropipéridin-1-yl)-4-(diméthylamino)but-2-én-1-one « A228 » (E)-N-(1,3-trans-3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino) cyclobutyl)-4-(diméthylamino)but-2-énamide « A235 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)-4-fluoropipéridin-1-yl)-3-(pipéridin-1-yl)propan-1-one « A236 » (E)-N-(1,3-cis-3-((6-amino-5-(4-(3-(trifluorméthyl) phénoxy) phényl) pyrimidi n-4-yl)amino) cyclobutyl)-4-(diméthylamino)but-2-énamide « A237 » N-(1,3-trans-3-((6-amino-5-(4-(3-(trifluorméthyl) phénoxy) phényl) pyrimidi n-4-yl)amino)cyclobutyl)acrylamide « A238 » N-(1,3-cis-3-((6-amino-5-(4-(3-(trifluorméthyl) phénoxy) phényl) pyrimidi n-4-yl)amino)cyclobutyl)acrylamide « A240 » N-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)-2-fluorophényl)acrylamide « A241 » N-(3-(4-amino-6-((4-phénoxyphényl)amino)pyrimidin-5-yl)phényl)acrylamide « A242 » N-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)acrylamide « A244 » N-(3-((2-amino-3-(4-phénoxyphényl)pyridin-4-yl)oxy)phényl)acrylamide « A246 » N-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)-4-fluorophényl)acrylamide « A247 » (R)-1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pipéridin-1-yl)prop-2-én-1-one « A250 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A251 » N-(5-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)-2,4-difluorophényl)acrylamide « A252 » (E)-N-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)-4-(diméthylamino)but-2-énamide « A253 » 1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pipéridin-1-yl)prop-2-én-1-one « A255 » N-(3-((5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)acrylamide « A258 » 4-(4-(3-acrylamideophénoxy)-6-aminopyrimidin-5-yl)-N-phénylbenzamide « A261 » N-(3-((6-amino-2'-(benzyloxy)-[5,5'-bipyrimidin]-4-yl)oxy)phényl)acrylamide « A262 » 1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pyrrolidin-1-yl)prop-2-én-1-one « A264 » N-(3-((6-amino-5-(4-((4-méthoxybenzyl)oxy)phényl)pyrimidin-4-yl)oxy)phényl)acrylamide « A265 » (E)-N-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)-4-morpholinobut-2-énamide « A266 » N-((1S,4S)-4-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide « A268 » N-(3-((6-amino-5-(6-phénoxypyridin-3-yl)pyrimidin-4-yl)oxy)phényl)acrylamide « A270 » N-(3-((3-(4-phénoxyphényl)pyridin-4-yl)oxy)phényl)acrylamide « A271 » N-(3-((2-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)acrylamide « A275 » (S)-1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pipéridin-1-yl)prop-2-én-1-one « A276 » N-((1R,4r)-4-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)cyclohexyl)acrylamide « A277 » N-(3-((6-amino-5-(4-fluor-3-méthoxyphényl)pyrimidin-4-yl)oxy)phényl)acrylamide « A278 » N-(3-((6-amino-5-(4-(2-hydroxypropan-2-yl)phényl)pyrimidin-4-yl)oxy)phényl)acrylamide « A280 » N-(4-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)acrylamide « A284 » 1-(3-((5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pipéridin-1-yl)prop-2-én-1-one « A286 » 1-(3-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A289 » N-(3-((6-amino-5-(4-isopropoxyphényl)pyrimidin-4-yl)oxy)phényl)acrylamide « A290 » (E)-N-(4-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)-4-(diméthylamino)but-2-énamide « A291 » N-(3-((6-amino-5-(5-méthoxypyridin-3-yl)pyrimidin-4-yl)oxy)phényl)acrylamide « A295 » (E)-N-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)-4-(4-(5-((4S)-2-oxohexahydro-1H-thieno[3,4-d]imideazol-4-yl)pentanoyl)pipérazin-1-yl)but-2-énamide « A297 » N-(4-((3-(4-phénoxyphényl)pyridin-4-yl)oxy)phényl)acrylamide « A298 » N-(1-(6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)pipéridin-3-yl)acrylamide « A299 » 1-(4-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pipéridin-1-yl)prop-2-én-1-one « A308 » N-(4-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)propionamide « A309 » N-((1-(6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)pipéridin-3-yl)méthyl)acrylamide « A318 » N-(3-((3-(4-phénoxyphényl)pyridin-4-yl)oxy)phényl)propionamide « A321 » N-(4-((3-(4-phénoxyphényl)pyridin-4-yl)oxy)phényl)propionamide « A326 » N-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)phényl)propionamide « A331 » (E)-3-(7-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)naphtalin-2-yl)-N,N-diméthylacrylamide « A333 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)propan-1-one « A334 » 1-(4-(((5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A335 » 1-(4-(((6-amino-5-(4-(pyridin-2-yloxy) phényl) pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-én-1-one « A336 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)but-2-yn-1-one « A337 » N4-((1-(6-chloropyridin-2-yl)pipéridin-4-yl)méthyl)-5-(4-phénoxyphényl)pyrimidin-4,6-diamine « A338 » 1-(4-(((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)oxy)méthyl)pipéridin-1-yl)prop-2-én-1-one « A340 » N-(3-((2-amino-3-(4-phénoxyphényl)pyridin-4-yl)oxy)phényl)but-2-ynamide « A341 » (R)-1-(3-((6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl)amino)pyrrolidin-1-yl)but-2-yn-1-one « A352 » N-{4-[4-(3-acryloylaminophénoxy)-6-aminopyrimidin-5-yl]phényl}benzamide
    et sels, formes tautomères et stéréoisomères pharmaceutiquement utilisables correspondant(e)s, y compris des mélanges de ceux-ci en tous rapports.
  5. Médicament comprenant au moins un composé de la formule II ou IV selon l'une ou plusieurs des revendications 1 à 4 et/ou un sel, une forme tautomère et un stéréoisomère pharmaceutiquement utilisable correspondant(e), y compris des mélanges de ceux-ci en tous rapports, et éventuellement des excipients et/ou adjuvants.
  6. Composé selon l'une ou plusieurs des revendications 1 à 4 pour une utilisation dans le traitement d'une tumeur solide, ou d'une tumeur du sang et du système immunitaire.
  7. Composé pour une utilisation selon la revendication 6, où la tumeur solide provient du groupe de tumeurs de l'épithélium squameux, de la vessie, de l'estomac, des reins, de la tête et du cou, de l'œsophage, du col de l'utérus, de la thyroïde, de l'intestin, du foie, du cerveau, de la prostate, du tract urogénital, du système lymphatique, du larynx et/ou du poumon, ou d'un adénocarcinome du poumon, de carcinomes du poumon non à petites cellules, d'un cancer pancréatique, de glioblastomes, d'un carcinome du sein ou d'un carcinome du côlon.
  8. Composé pour une utilisation selon la revendication 6, où la tumeur du sang et du système immunitaire provient du groupe d'une leucémie monocytaire, d'une leucémie myéloïde aiguë, d'une leucémie myéloïde chronique, d'une leucémie lymphatique aiguë, et/ou d'une leucémie lymphatique chronique.
  9. Médicament comprenant au moins un composé de la formule II ou IV selon l'une ou plusieurs des revendications 1 à 4 et/ou un sel, une forme tautomère et un stéréoisomère pharmaceutiquement utilisable correspondant(e), y compris des mélanges de ceux-ci en tous rapports, et au moins un ingrédient actif médicamenteux supplémentaire.
  10. Ensemble (kit) constitué d'emballages séparés de
    (a) une quantité efficace d'un composé de la formule II ou IV selon l'une ou plusieurs des revendications 1 à 4 et/ou d'un sel, d'une forme tautomère et d'un stéréoisomère pharmaceutiquement utilisable correspondant(e), y compris des mélanges de ceux-ci en tous rapports, et
    (b) une quantité efficace d'un ingrédient actif médicamenteux supplémentaire.
EP12728011.3A 2011-06-10 2012-06-10 Compositions et procédés de production de composés pyrimidine et pyridine ayant une activité inhibitrice de btk Active EP2718270B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SI201232002T SI2718270T1 (sl) 2011-06-10 2012-06-10 Sestavki in postopki za proizvodnjo pirimidinskih in piridinskih spojin z BTK inhibitorno aktivnostjo
EP22169537.2A EP4056562A1 (fr) 2011-06-10 2012-06-10 Inhibiteurs hétérocycliques de la tyrosine kinase de bruton
HRP20220886TT HRP20220886T1 (hr) 2011-06-10 2012-06-10 Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću
RS20220687A RS63418B1 (sr) 2011-06-10 2012-06-10 Kompozicije i metode za proizvodnju jedinjenja pirimidina i piridina sa btk inhibitorskom aktivnošću

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161495773P 2011-06-10 2011-06-10
PCT/US2012/041803 WO2012170976A2 (fr) 2011-06-10 2012-06-10 Compositions et procédés de production de composés pyrimidine et pyridine ayant une activité inhibitrice de btk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22169537.2A Division EP4056562A1 (fr) 2011-06-10 2012-06-10 Inhibiteurs hétérocycliques de la tyrosine kinase de bruton

Publications (2)

Publication Number Publication Date
EP2718270A2 EP2718270A2 (fr) 2014-04-16
EP2718270B1 true EP2718270B1 (fr) 2022-04-27

Family

ID=46317541

Family Applications (2)

Application Number Title Priority Date Filing Date
EP22169537.2A Withdrawn EP4056562A1 (fr) 2011-06-10 2012-06-10 Inhibiteurs hétérocycliques de la tyrosine kinase de bruton
EP12728011.3A Active EP2718270B1 (fr) 2011-06-10 2012-06-10 Compositions et procédés de production de composés pyrimidine et pyridine ayant une activité inhibitrice de btk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP22169537.2A Withdrawn EP4056562A1 (fr) 2011-06-10 2012-06-10 Inhibiteurs hétérocycliques de la tyrosine kinase de bruton

Country Status (24)

Country Link
US (4) US9073947B2 (fr)
EP (2) EP4056562A1 (fr)
JP (4) JP2014517016A (fr)
KR (5) KR20140007954A (fr)
CN (2) CN106831732B (fr)
AU (2) AU2012267491B2 (fr)
BR (1) BR112013030442B1 (fr)
CA (1) CA2833771C (fr)
CY (1) CY1125494T1 (fr)
DK (1) DK2718270T3 (fr)
EA (2) EA031153B1 (fr)
ES (1) ES2923760T3 (fr)
HR (1) HRP20220886T1 (fr)
HU (1) HUE059230T2 (fr)
IL (1) IL229863A (fr)
LT (1) LT2718270T (fr)
MX (2) MX354412B (fr)
PL (1) PL2718270T3 (fr)
PT (1) PT2718270T (fr)
RS (1) RS63418B1 (fr)
SG (3) SG10201604682VA (fr)
SI (1) SI2718270T1 (fr)
WO (1) WO2012170976A2 (fr)
ZA (1) ZA201307632B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201604682VA (en) 2011-06-10 2016-07-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
CN104822663B (zh) * 2012-10-04 2017-03-08 犹他大学研究基金会 作为酪氨酸受体激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
WO2014093230A2 (fr) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk
KR20150113195A (ko) * 2013-03-05 2015-10-07 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
SG10201900954SA (en) * 2013-03-11 2019-02-27 Merck Patent Gmbh Heterocycles as Modulators of Kinase Activity
BR112015025260B1 (pt) 2013-04-25 2021-11-03 Beigene, Ltd Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso
CN104140395B (zh) * 2013-05-08 2018-07-24 中国医学科学院药物研究所 丁炔酰胺衍生物及其制法和药物组合物与用途
CN104447727B (zh) * 2013-09-02 2018-04-27 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
RS63571B9 (sr) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
CA2920059A1 (fr) * 2013-09-22 2015-03-26 Calitor Sciences, Llc Composes d'aminopyrimidine substituee et procedes d'utilisation
SG11201602070TA (en) 2013-09-30 2016-04-28 Beijing Synercare Pharma Tech Co Ltd Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
HUE044683T2 (hu) * 2013-10-21 2019-11-28 Merck Patent Gmbh Heteroaril vegyületek mint BTK inhibitorok és alkalmazásuk
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
AU2014361800B2 (en) 2013-12-13 2020-05-07 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2015136398A1 (fr) 2014-03-12 2015-09-17 Novartis Ag Combinaison comprenant un inhibiteur de btk et un inhibiteur d'atk
WO2015164294A1 (fr) * 2014-04-22 2015-10-29 The Feinstein Institute For Medical Research Traitement de tumeurs solides par inhibition de mrk/zak
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
WO2016025650A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur de erk et d'un inhibiteur cdk4/6 et méthodes associées
EP3179858B1 (fr) 2014-08-13 2019-05-15 Celgene Car Llc Formes et compositions d'un inhibiteur d'erk
WO2016025651A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur de erk et d'un inhibiteur de tor et méthodes associées
WO2016025567A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Formulations orales et utilisations de celles-ci
TW201618785A (zh) * 2014-08-13 2016-06-01 西建阿維拉米斯研究公司 使用ｅｒｋ抑制劑的治療方法
EP3209648B1 (fr) 2014-10-22 2020-03-11 Dana-Farber Cancer Institute, Inc. Composés contenant des groupes thiazolyle pour le traitement de maladies prolifératives
EP3230737A1 (fr) * 2014-12-11 2017-10-18 Merck Patent GmbH Dosages pour inhibiteurs de la btk
CN105837576B (zh) * 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
CN105924433B (zh) * 2015-02-28 2020-12-22 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
CN104844573A (zh) * 2015-04-17 2015-08-19 中国药科大学 嘧啶类btk抑制剂、其制备方法及医药用途
HUE046328T2 (hu) 2015-05-26 2020-03-30 Morphosys Ag CD19 elleni ellenanyag és Bruton-féle tirozin-kináz gátlójának kombinációja és a kombináció alkalmazásai
WO2017047602A1 (fr) 2015-09-18 2017-03-23 科研製薬株式会社 Dérivé biaryle et médicament le contenant
ES2912059T3 (es) * 2015-11-04 2022-05-24 Merck Patent Gmbh Inhibidor de BTK para su uso en el tratamiento del cáncer
PL3377484T3 (pl) * 2015-11-17 2024-04-08 Merck Patent Gmbh Metody dla terapii stwardnienia rozsianego z użyciem związków pirymidynowych i pirydynowych z aktywnością inhibitorową dla btk
KR20180094923A (ko) * 2015-12-24 2018-08-24 교와 핫꼬 기린 가부시키가이샤 α, β 불포화 아미드 화합물
CN105732638B (zh) * 2016-01-22 2018-01-30 成都倍特药业有限公司 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
PT3468966T (pt) * 2016-06-10 2020-11-10 Vitae Pharmaceuticals Llc Inibidores da interação menina-mll
WO2018007885A1 (fr) 2016-07-05 2018-01-11 Beigene, Ltd. Association d'un antagoniste de pd-1 et d'un inhibiteur du raf pour le traitement du cancer.
JP7402685B2 (ja) 2016-08-16 2023-12-21 ベイジーン スウィッツァーランド ゲーエムベーハー （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
BR112019005337A2 (pt) 2016-09-19 2019-08-27 Mei Pharma Inc terapia combinada
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
US10464923B2 (en) * 2017-02-27 2019-11-05 Merck Patent Gmbh Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone
CA3062294A1 (fr) * 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Composes tricycliques non fusionnes
TWI804498B (zh) * 2017-06-23 2023-06-11 日商協和麒麟股份有限公司 α、β不飽和醯胺化合物
WO2019001417A1 (fr) 2017-06-26 2019-01-03 Beigene, Ltd. Immunothérapie pour carcinome hépatocellulaire
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
CN109824603B (zh) * 2017-11-23 2021-03-12 浙江省化工研究院有限公司 一种嘧啶胺类化合物、其制备方法及应用
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
EP3789040A4 (fr) 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. Agent préventif et/ou thérapeutique pour maladie auto-immune comprenant un composé ayant une activité inhibitrice de btk en tant que principe actif
CN112313214A (zh) * 2018-06-19 2021-02-02 默克专利有限公司 1-(4-{[6-氨基-5-(4-苯氧基-苯基)-嘧啶-4-基氨基]-甲基}-4-氟代-哌啶-1-基)-丙烯酮及其盐形式的新晶体形式以及获得方法
CN112437665A (zh) * 2018-07-20 2021-03-02 默克专利有限公司 用于治疗及预防多发性硬化症的方法中的经取代氨基-嘧啶化合物
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
WO2020043321A1 (fr) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Combinaisons synergiques de sensibilisateurs d'agent de déplétion en acides aminés (aadas) et d'agents de déplétion en acides aminés (aada), et leurs procédés thérapeutiques d'utilisation
KR102190019B1 (ko) 2018-10-23 2020-12-15 삼진제약주식회사 쇼그렌 증후군 예방 또는 치료용 조성물
CN111499613B (zh) * 2019-01-31 2023-05-12 浙江海正药业股份有限公司 N-甲酰胺衍生物、其制备方法及其在医药上的用途
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2020249001A1 (fr) 2019-06-10 2020-12-17 百济神州瑞士有限责任公司 Comprimé solide pour voie orale comprenant un inhibiteur de tyrosine kinase de bruton et son procédé de préparation
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2021211782A1 (fr) * 2020-04-15 2021-10-21 Telios Pharma, Inc. Méthodes de traitement d'une lésion pulmonaire aiguë et d'un syndrome de détresse respiratoire aiguë
AU2021325431B2 (en) 2020-08-14 2024-01-18 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
CN112250666B (zh) * 2020-10-09 2022-01-14 广东东阳光药业有限公司 取代的嘧啶类化合物及其用途
JP2023551679A (ja) * 2020-12-02 2023-12-12 テリオス ファーマ， インコーポレイテッド 眼科疾患を治療するための方法及び組成物
MX2023006854A (es) 2020-12-10 2023-07-20 Genzyme Corp Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (fr) 2021-04-02 2022-10-06 Biogen Ma Inc. Méthodes de traitement combiné de la sclérose en plaques
CA3216260A1 (fr) * 2021-04-27 2022-11-03 Nathanael S. Gray Inhibiteurs du facteur de transcription a domaine associe transcriptionnel ameliore (tead) et leurs utilisations
JP2024517945A (ja) 2021-05-14 2024-04-23 シンダックス ファーマシューティカルズ， インコーポレイテッド メニン－ｍｌｌ相互作用の阻害剤
WO2023280272A1 (fr) * 2021-07-07 2023-01-12 杭州领业医药科技有限公司 Formes cristallines d'évobrutinib et son sel, procédé de préparation correspondant et utilisation associée
EP4370513A1 (fr) 2021-07-15 2024-05-22 Sandoz Ag Forme mandélate de 1-(4-(((6-amino-5-(4-phénoxyphényle)pyrimidin-4-yl)amino)méthyl)pipéridin-1-yl)prop-2-en-1-one
CN115703770B (zh) * 2021-08-10 2025-07-18 深圳范恩柯尔精准医疗有限公司 嘧啶胺类化合物及其组合物和用途
CN116199668B (zh) * 2021-09-13 2025-06-13 都创(上海)医药开发有限公司 Evobrutinib化合物盐型及其制备方法
TWI878871B (zh) * 2022-05-09 2025-04-01 大陸商浙江同源康醫藥股份有限公司 多環類化合物及其用途
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
CA3259743A1 (fr) * 2022-06-22 2023-12-28 Principia Biopharma Inc. Procédés de fabrication d'inhibiteurs de btk modifiés
JP2025520698A (ja) 2022-06-24 2025-07-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫疾患および炎症性疾患のための処置レジメン
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024091511A1 (fr) * 2022-10-25 2024-05-02 Light Horse Therapeutics, Inc. Inhibiteurs de tead heterocycliques
WO2024099241A1 (fr) * 2022-11-07 2024-05-16 天津征程医药科技有限公司 Dérivé de pyrimidine deutéré et composition pharmaceutique le comprenant
WO2025244678A1 (fr) 2024-05-21 2025-11-27 Telios Pharma Inc. Méthodes de traitement de la mastocytose systémique indolent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029804A1 (fr) * 2009-09-10 2011-03-17 F. Hoffmann-La Roche Ag Inhibiteurs de jak
WO2011099764A2 (fr) * 2010-02-09 2011-08-18 Hanmi Holdings Co., Ltd. Nouveau dérivé de la pyrimidine pour l'inhibition de la croissance des cellules cancéreuses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB712595A (en) * 1952-01-30 1954-07-28 Rhone Poulenc Sa New pyrimidines and processes for their production
US5002949A (en) * 1990-05-01 1991-03-26 American Home Products Corporation 5-substituted-6-aminopyrimidine derivatives
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5055476A (en) 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
JPH0583246A (ja) * 1991-07-29 1993-04-02 Fujitsu Ltd 網状回線の通信方式
JPH08283246A (ja) 1994-06-01 1996-10-29 Nippon Soda Co Ltd ピリミジン誘導体、その製造方法及び有害生物防除剤
ES2079323B1 (es) 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19604190A1 (de) * 1996-02-06 1997-08-07 Hoechst Ag Nagelwachstumsfördernde Zubereitungen
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
EP1348706B1 (fr) * 2000-12-08 2009-08-19 Takeda Pharmaceutical Company Limited Derives thiazole substitues porteurs de groupes 3-pyridyl, procede d'elaboration et leur utilisation
GB0115602D0 (en) * 2001-06-26 2001-08-15 Syngenta Participations Ag Organic compounds
US20050171131A1 (en) * 2003-09-26 2005-08-04 Christi Kosogof Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
EP1711495A2 (fr) 2004-01-23 2006-10-18 Amgen Inc. Quinolines, chinazolines, pyridines et pyrimidines et leur utilsation dans le traitement d'inflammation, angiogenèse et le cancer
KR20070090172A (ko) * 2004-11-04 2007-09-05 버텍스 파마슈티칼스 인코포레이티드 단백질 키나아제의 억제제로서 유용한피라졸로[1,5-ａ]피리미딘
EP1917017B1 (fr) 2005-03-04 2010-02-03 Alsgen, Inc. Traitement de la sclerose amyotrophique laterale avec la pyrimethamine et des analogues
GB0512844D0 (en) * 2005-06-23 2005-08-03 Novartis Ag Organic compounds
WO2007056151A2 (fr) 2005-11-03 2007-05-18 Irm Llc Composes et compositions d’inhibiteurs de proteine kinases
DE102005060449A1 (de) * 2005-12-17 2007-06-21 Bayer Cropscience Ag Carboxamide
JP5236499B2 (ja) 2006-01-27 2013-07-17 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤
BRPI0707666A2 (pt) 2006-02-06 2011-05-10 Irm Llc compostos e composiÇÕes como inibidores de proteÍna cinase
US8063225B2 (en) * 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
AR063278A1 (es) * 2006-10-12 2009-01-14 Xenon Pharmaceuticals Inc Compuestos de espiro-oxindol, una composicion farmaceutica que los comprende y su uso para el tratamiento de enfermedades o condiciones mediadas por los canales de sodio.
US20080255155A1 (en) * 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
WO2008058229A1 (fr) * 2006-11-08 2008-05-15 Bristol-Myers Squibb Company Composés de pyridinone
EA017865B1 (ru) * 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2170887A2 (fr) * 2007-06-07 2010-04-07 Amgen Inc. Modulateurs de la raf kinase et leurs méthodes d'utilisation
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2702674C (fr) * 2007-10-19 2016-05-03 Avila Therapeutics, Inc. Composes heteroaryles et leurs utilisations
WO2009122180A1 (fr) * 2008-04-02 2009-10-08 Medical Research Council Dérivés de pyrimidine capables d’inhiber une ou plusieurs kinases
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
AR074343A1 (es) * 2008-11-14 2011-01-12 Amgen Inc Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
PL2473049T3 (pl) * 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
US9029359B2 (en) * 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
UY33304A (es) * 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
CA2800998A1 (fr) * 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Analogues et amides de pyridone presentant des activites anticancereuse et antiproliferative
US8497265B2 (en) * 2010-05-13 2013-07-30 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
AU2011253057B2 (en) * 2010-05-13 2014-11-20 Amgen Inc. Nitrogen heterocyclic compounds useful as PDE10 inhibitors
US8673922B2 (en) * 2010-07-15 2014-03-18 Bristol-Myers Squibb Company Azaindazole compounds
SG10201604682VA (en) * 2011-06-10 2016-07-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
CN106946796B (zh) * 2011-09-12 2020-05-08 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
TWI566701B (zh) 2012-02-01 2017-01-21 日本農藥股份有限公司 芳烷氧基嘧啶衍生物及包含該衍生物作為有效成分的農園藝用殺蟲劑及其使用方法
TW201414734A (zh) * 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029804A1 (fr) * 2009-09-10 2011-03-17 F. Hoffmann-La Roche Ag Inhibiteurs de jak
WO2011099764A2 (fr) * 2010-02-09 2011-08-18 Hanmi Holdings Co., Ltd. Nouveau dérivé de la pyrimidine pour l'inhibition de la croissance des cellules cancéreuses

Also Published As

Publication number Publication date
KR20170021367A (ko) 2017-02-27
JP2016185953A (ja) 2016-10-27
WO2012170976A2 (fr) 2012-12-13
AU2012267491B2 (en) 2017-07-06
AU2017235978B2 (en) 2019-04-04
JP2014517016A (ja) 2014-07-17
CN103814016B (zh) 2017-03-08
AU2017235978A1 (en) 2017-10-19
SG10201604682VA (en) 2016-07-28
IL229863A0 (en) 2014-03-06
ZA201307632B (en) 2017-06-28
SG194219A1 (en) 2013-11-29
HRP20220886T1 (hr) 2022-10-28
HK1197234A1 (en) 2015-01-09
SG10201801668WA (en) 2018-03-28
US10016448B2 (en) 2018-07-10
US9580449B2 (en) 2017-02-28
EA031153B1 (ru) 2018-11-30
ES2923760T3 (es) 2022-09-30
KR20190011343A (ko) 2019-02-01
BR112013030442A2 (pt) 2016-09-27
KR20140007954A (ko) 2014-01-20
KR20150144817A (ko) 2015-12-28
CA2833771A1 (fr) 2012-12-13
EP2718270A2 (fr) 2014-04-16
US20140162983A1 (en) 2014-06-12
US20150259363A1 (en) 2015-09-17
PL2718270T3 (pl) 2022-08-08
EA027584B1 (ru) 2017-08-31
US20170136048A1 (en) 2017-05-18
IL229863A (en) 2017-06-29
KR20180084153A (ko) 2018-07-24
AU2012267491A1 (en) 2013-10-31
KR101880966B1 (ko) 2018-07-23
MX354412B (es) 2018-03-05
US10413562B2 (en) 2019-09-17
JP6853204B2 (ja) 2021-03-31
LT2718270T (lt) 2022-08-10
US20180243324A1 (en) 2018-08-30
CN103814016A (zh) 2014-05-21
PT2718270T (pt) 2022-07-29
CN106831732A (zh) 2017-06-13
JP6298096B2 (ja) 2018-03-20
EA201301353A1 (ru) 2014-05-30
DK2718270T3 (da) 2022-08-01
CY1125494T1 (el) 2025-05-09
US9073947B2 (en) 2015-07-07
BR112013030442B1 (pt) 2021-11-09
JP2020073593A (ja) 2020-05-14
WO2012170976A3 (fr) 2013-04-11
CN106831732B (zh) 2019-12-24
CA2833771C (fr) 2021-08-03
MX373151B (es) 2020-04-21
JP2018115165A (ja) 2018-07-26
SI2718270T1 (sl) 2022-11-30
RS63418B1 (sr) 2022-08-31
MX2013012983A (es) 2013-12-06
JP6849834B2 (ja) 2021-03-31
EA201790228A1 (ru) 2017-08-31
HUE059230T2 (hu) 2022-10-28
EP4056562A1 (fr) 2022-09-14

Similar Documents

Publication Publication Date Title
EP2718270B1 (fr) Compositions et procédés de production de composés pyrimidine et pyridine ayant une activité inhibitrice de btk
EP4014977A1 (fr) Composés pyrimidine ayant une activité inhibitrice de la btk pour utilisation dans le traitement du cancer
HK1237779A1 (en) Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
HK1197234B (en) Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
HK1237779B (zh) 生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20220886

Country of ref document: HR

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131031

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150309

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220121

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: MERCK PATENT GMBH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1486870

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012078099

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20220427

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2718270

Country of ref document: PT

Date of ref document: 20220729

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20220725

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20220726

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20220401459

Country of ref document: GR

Effective date: 20220808

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E022501

Country of ref document: EE

Effective date: 20220712

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2923760

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220930

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20220886

Country of ref document: HR

Payment date: 20220727

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20220886

Country of ref document: HR

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E059230

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012078099

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220427

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220427

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20230130

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230518

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20220886

Country of ref document: HR

Payment date: 20230531

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20220886

Country of ref document: HR

Payment date: 20240429

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20240510

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250520

Year of fee payment: 14

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20220886

Country of ref document: HR

Payment date: 20250527

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20250520

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250520

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250520

Year of fee payment: 14

Ref country code: DK

Payment date: 20250520

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20250520

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20250604

Year of fee payment: 14

Ref country code: RS

Payment date: 20250604

Year of fee payment: 14

Ref country code: NO

Payment date: 20250522

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20250623

Year of fee payment: 14

Ref country code: LU

Payment date: 20250523

Year of fee payment: 14

Ref country code: BE

Payment date: 20250520

Year of fee payment: 14

Ref country code: IT

Payment date: 20250520

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HR

Payment date: 20250527

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20250520

Year of fee payment: 14

Ref country code: PT

Payment date: 20250521

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20250613

Year of fee payment: 14

Ref country code: EE

Payment date: 20250605

Year of fee payment: 14

Ref country code: FR

Payment date: 20250520

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20250530

Year of fee payment: 14

Ref country code: BG

Payment date: 20250527

Year of fee payment: 14

Ref country code: GR

Payment date: 20250522

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20250610

Year of fee payment: 14

Ref country code: AT

Payment date: 20250522

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250528

Year of fee payment: 14

Ref country code: SK

Payment date: 20250526

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20250529

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250522

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20250527

Year of fee payment: 14

Ref country code: SE

Payment date: 20250520

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250701

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250527

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250701

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20250522

Year of fee payment: 14